The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.

Bone Marrow Transplant · 2019 · PMC6957459 · PMID 30728439

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

The increase for sickle cell disease HCT is clearly (>95% CI for the prediction model) significant, for thalassemia of borderline significance.

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.